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Antiretroviral therapy (ART) fails to cure HIV-1 infection because latent 
proviruses persist in resting CD4
+
 T cells. T cell activation reverses latency, but >99% of 
proviruses are not induced to release infectious virus after maximum in vitro T cell 
activation under standard viral outgrowth assay conditions. These non-induced proviruses 
are generally considered defective but have never been characterized.  
 
Using limiting dilution near-full length nested PCR and Poisson distribution 
analysis, we characterized 213 clones of non-induced proviruses from eight aviremic 
patients on suppressive ART. Most (88.3%) of the non-induced proviruses are defective, 
including 45.5% large internal deletions, 32.4% APOBEC-mediated G→A 
hypermutations, 6.6% mutations/deletions in the cis-acting element, and 3.8% 
insertions/nonsense mutations. 
 
Strikingly, 11.7% of the non-induced proviruses have intact genomes. Using 
direct sequencing and de novo genome synthesis, we reconstructed six full-length non-
induced proviral clones and demonstrated growth kinetics comparable to four 
reconstructed induced proviruses from the same patients. 
 
Using luciferase assay to measure non-induced proviral LTR activity, we found 
that non-induced proviruses have intact promoter function unless they are hypermutated. 
Using limiting dilution bisulfite sequencing, we found that non-induced proviruses have 




integrated into active transcription units. We demonstrated that these non-induced 
proviruses, though not induced after in vitro maximum T cell activation, can be 
reactivated after repeated stimuli. We propose that maximum T cell activation does not 
lead to maximum non-induced provirus activation. Rather, activation of non-induced 
proviruses is stochastic. 
 
Thus, it cannot be excluded that non-induced proviruses may become activated in 
vivo. The discovery of replication-competent non-induced proviruses indicates that the 
size of the latent reservoir, and hence the barrier to cure, may be ~60-fold greater than 
previously estimated.  
 
Underestimation of intact proviruses by viral outgrowth assays could be reflected 
in delayed viral rebound after an apparent “cure”, and overestimation of latent reservoir 
size resulting from detection of defective proviruses by PCR assays could result in 
prolonged, excessive exposure to toxic latency reversing agents. Thus, the molecular 
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Chapter 1. Introduction 
Despite prolonged antiretroviral therapy (ART), HIV-1 persists as 
transcriptionally inactive proviruses in resting memory CD4
+
 T cells (Chun et al., 1997; 
Finzi et al., 1997; Wong et al., 1997).  This latent reservoir has a long half-life, 
preventing cure by ART alone (Finzi et al., 1997; Siliciano et al., 2003; Strain et al., 
2003).  In resting CD4
+
 T cells, the lack of active forms of key cellular transcription 
factors (Bohnlein et al., 1988; Duh et al., 1989; Ganesh et al., 2003; Kinoshita et al., 1997; 
Nabel and Baltimore, 1987; West et al., 2001) and of HIV-1 Tat and its cellular cofactors 
(Cujec et al., 1997; Herrmann and Rice, 1995; Jones and Peterlin, 1994; Kao et al., 1987; 
Selby and Peterlin, 1990; Tyagi et al., 2010) limits the initiation and elongation, 
respectively, of viral transcription (Lassen et al., 2004; Williams and Greene, 2007).  The 
latent reservoir may thus be established when activated CD4
+
 T cells become infected as 
they revert back to a resting memory state.  In addition, DNA methylation and repressive 
histone modifications may promote silencing of proviruses (Blazkova et al., 2009; Coull 
et al., 2000; He and Margolis, 2002; Kauder et al., 2009; Van Lint et al., 1996; Verdin et 
al., 1993; Williams et al., 2006). 
A major approach to eradicating HIV-1 involves reversing latency in patients on 
ART (Deeks, 2012; Richman et al., 2009).  Cells harboring induced proviruses could then 
be lysed by HIV-1-specific cytolytic T lymphocytes (CTL) (Shan et al., 2012), while new 
rounds of infection are blocked by ART.  Clinical trials exploring this strategy have used 
the histone deacetylase inhibitors valproic acid (Lehrman et al., 2005), vorinostat (Archin 





Accurate measurement of the latent reservoir is essential for evaluating 
eradication strategies.  If the latent reservoir is completely eradicated, ART can be 
discontinued without rebound viremia.  Interruption before complete eradication will 
likely result in rebound (Davey et al., 1999) and repopulation of the latent reservoir, 
nullifying the eradication effort. 
The standard assay for latent reservoir size is a viral outgrowth assay (viral 
outgrowth assay (Finzi et al., 1997; Siliciano and Siliciano, 2005), which measures the 
frequency of resting CD4
+
 T cells that produce infectious virus after a single round of 
maximum in vitro T cell activation.  Limiting dilutions of resting CD4
+
 T cells are 
stimulated with the mitogen phytohemagglutinin (PHA), which reverses latency by 
inducing T cell activation.  Released viruses are expanded by addition of CD4
+
 T 
lymphoblasts from HIV-1-negative donors.  Culture supernatants are examined for 
exponential viral growth by enzyme-linked immunosorbant assay (ELISA) for HIV-1 p24.  





 T cells (Eriksson et al., 2013). 
It has been assumed that latent reservoir size can be assessed with agents like 
PHA that induce uniform activation of CD4
+
 T cells (Hermankova et al., 2003; Patel et 
al., 1988).  However, the frequency of latently infected cells detected in the viral 
outgrowth assay is on average 300 fold lower than the frequency of resting CD4
+
 T cells 
that harbor proviruses detectable by PCR (Eriksson et al., 2013).  Thus at limiting 
dilution in the viral outgrowth assay, negative wells contain many proviruses, which we 
designate non-induced proviruses. The non-induced proviruses are generally considered 




the challenge presented by the latent reservoir depends on whether non-induced 
proviruses can be induced in vivo.  We present here the first molecular characterization of 
non-induced proviruses, the results of which provide disturbing new insights into the 
difficulty of curing HIV-1 infection. 
The latent reservoir in resting CD4
+
 T cells is the major barrier to HIV-1 
eradication, and as efforts to cure the infection proceed, accurate measurement of latent 
reservoir size will be essential.  This study provides a molecular basis for understanding 
measures of the latent reservoir.  Through an analysis of proviruses that did not give rise 
to infectious virus following a single round of T cell activation (non-induced proviruses), 
we have provided a definitive explanation for the large discrepancy between results of 
PCR and culture assays of latent reservoir size.  In addition, the discovery of intact non-
induced proviruses indicates that the size of the latent reservoir may be much greater than 
previously thought.  We reconstructed full-length, intact non-induced proviruses from 
multiple patients, and all showed growth kinetics comparable to induced proviruses from 
the same patient and a reference isolate.  These intact non-induced proviruses are not 
detected in standard culture assays but may nevertheless prevent cure.  Thus the present 
study provides new insights into the extent of the challenge posed by the latent reservoir 








For determining the size of the latent reservoir, the current standard is the viral 
outgrowth assay (86 Siliciano,J.D. 2005; 220 Finzi,D. 1997).  This assay measures the 
frequency of resting CD4
+
 T cells that produce replication-competent virus after as single 
round of maximum in vitro T cell activation.   Limiting dilutions of resting CD4
+
 T cells 
purified from patients on suppressive ART are activated with PHA. PHA, a potent 
mitogenic lectin, cross-links T cell receptor/CD3 complex, activates phospholipase C and 
protein kinase C (Mustelin et al., 1990), up-regulates interleukin-2 (IL-2) and IL-2 
receptor (CD25) expression (Depper et al., 1985), resulting in an autocrine stimulation 
and T cell proliferation.  PHA provides 100% colony forming ability in CD4
+
 T cells 
(Hermankova et al., 2003; Patel et al., 1988) and reverses latency by global T cell 
activation, as one of the most potent reagent used in vitro to reverse latency (Yang et al., 
2009b), in a greater efficiency than most latency reversing agents tested to date.  PHA 
was washed out after one day of culture to reduce cytotoxicity.  Viruses released into the 
supernatant following PHA activation are further amplified by co-culture with two 
additions of allogeneic CD4
+
 T lymphoblasts.  Culture supernants are examined for 
exponential viral growth p24 ELISA for HIV-1 Gag antigen on day 14 – 21 of culture, 
and positive wells are considered to have contained at least one latently infected cells 




the frequency of latently infected cells (Siliciano and Siliciano, 2005).  In patients on 




 T cells. 
Unlike human endogenous retroviruses, which are silenced during embryogenesis 
(Rowe et al., 2010) and generally thought to be harmless, HIV-1 integrates into 
terminally differentiated CD4
+
 T cells and does not follow silencing mechanisms seen in 
endogenous retroviruses (Rowe et al., 2010).  Although they were not induced by in vitro 
activation using PHA, it does not mean that they would never be reactivated in vivo. 
Unlike PCR based methods, which solely represent the presence of DNA 
fragment regardless of being intact or defective, the relatively high detection limit of 
viruses in the supernatant indicate the presence of multiple rounds of exponential viral 
propagation, reflecting presence of functional and  replication competent proviruses.  The 
detection limit of the viral outgrowth assay is 104,167 HIV-1 RNA copies/mL, which 
was calculated as: 3 fg HIV-1 p24/50 RNA copies (Barletta et al., 2004) x 6.25 pg/mL 
detection limit = 104,167 copies/mL.  However, with this relatively high detection limit, 
p24 negative wells are not merely a reflection of false negative results of an insensitive 
detection assay.  Rather, it has been confirmed that all p24 negative wells remain 
negative after a more sensitive mRNA detection method (Laird et al., 2013) down to 555 
copies/mL (which was calculated by the fact that detecting one copy/well of quantitative 
PCR equals to 1.8 µL of culture supernatant in this assay). 
 The main obstable to isolate full-length proviral DNA from the viral outgrowth 
cultures is that the patient resting CD4
+
 T cells (for example 0.2 or 0.04 million per well) 
are outnumbered by the healthy donor lymphoblasts (1 million per well x 2 additions = 2 




DNA is technically challenging.  An alternative way is to separate patient cells and 
healthy donor lymphoblasts by a transwell culture system, with a 0.4 µm membrane 
permeable for viruses and nutrients but impermeable for cells, to obtain a pure population 
of patient cells for further proviral DNA isolation.  This separation, however, prevents 
direct intercellular contact, which may or may not reduce the efficiency of viral 
propagation, and hence the sensitivity of the viral outgrowth assay.  We here 
demonstrated that our transwell viral outgrowth assay provides maximum T cell 
activation and comparable sensitivity with the standard viral outgrowth assay. 
 
Methods 
Viral outgrowth assay 
Viral outgrowth assays were performed as described (Finzi et al., 1997; Siliciano 
and Siliciano, 2005).  Briefly, resting CD4
+
 T cells were isolated from patients under 
suppressive ART with undetectable plasma viral load for >6 months prior to enrollment 
to ensure no preintegration latency.  Using magnetic microbead selection (Miltenyi 
Biotec), CD4
+
 T cells were first isolated using negative selection, and CD25, CD69 and 
HLA-DR expressing cells were removed by positive selection.  Standard and transwell 
cultures were preformed side by side using the same population of patient resting CD4
+
 T 
cells, irradiated allogeneic healthy donor peripheral blood mononuclear cells (PBMCs) 
and CD8-deplted healthy donor lymphoblasts.  The volume of culture medium and the 
total number of cells per well was equal for these two culture conditions.  In transwell 
cultures, patient resting CD4
+
 T cells and irradiated PBMC from healthy donors were 




pores.  The irradiated PBMCs are necessary for optimal PHA activation but die during 
the culture period, leaving the upper chamber containing a pure population of patient 
CD4
+
 T cells.  CD8-depleted allogeneic lymphoblasts were added to the lower chamber 
of the transwell culture in the same numbers as for standard cultures. 
After 21 days of culture, 180 µL of culture supernatant were subjected to p24 
ELISA (Perkin Elmer).  P24 ELISA >6.25 ng/µL were determined as positive. 
 
Results 
To analyze proviruses that did not give rise to infectious virus in the viral 
outgrowth assay (non-induced proviruses), we first established that the conditions were 
sufficient to activate 100% of resting CD4
+
 T cells.  Resting CD4
+
 T cells from patients 
on suppressive ART for >6 months (range, 19–108) were labeled with carboxyfluorescein 
succinimidyl ester (CFSE) and stimulated with PHA and irradiated allogeneic PBMC 
under conditions used in the viral outgrowth assay. By day 7, >99.8% of patient cells had 
divided at least once (Figure 1A), confirming that PHA causes uniform T cell activation. 
In the viral outgrowth assay, viruses released after reversal of latency replicate in 
healthy donor CD4
+
 lymphoblasts added to the cultures.  To facilitate cloning of non-
induced proviruses, we explored whether comparable levels of activation and viral 
outgrowth could be achieved in transwell cultures in which patient cells were separated 
from donor lymphoblasts by a cell-impermeable membrane (Figure 1B).  In side-by-side 
comparison with standard viral outgrowth assay cultures from ten patients, transwell 
cultures showed comparable cellular activation in both p24 positive and negative wells, 




Transwell cultures also showed viral outgrowth comparable to that observed for standard 
viral outgrowth assay cultures (Figure 1D).  Non-induced proviruses were thus cloned 




Although difficult and time-consuming, the viral outgrowth assay (Eriksson et al., 
2013; Finzi et al., 1997), which has recently been simplified (Laird et al., 2013), does 
allow detection of cells harboring replication-competent virus.  We first explored to make 
sure this is not simply an issue of assay sensitivity.  We showed that the PHA stimulation 
activates all resting CD4
+
 T cells as assessed by proliferation and activation marker 
expression.  Using prolonged culture and sensitive RT-PCR assays, we also verified that 
wells from which non-induced proviruses were obtained were truly negative for viral 
outgrowth.  It is also unlikely that these p24 negative wells remained negative because of 
reduced viral fitness, as we showed that intact non-induced proviruses had growth 
kinetics comparable to induced viruses from p24 positive wells (see below).  Taken 
together, these results confirm that we are examining a population of intact proviruses 






Figure 1. Viral outgrowth assay conditions achieve maximum in vitro activation and 
outgrowth 
(A) CFSE fluorescence in labeled patient resting CD4
+
 T cells on day 0 (light green) and 
day seven (dark green) of the viral outgrowth assay. 
(B) Separation of patient cells from healthy donor CD4
+
 lymphoblasts in a transwell 
version of the viral outgrowth assay.  Patient cells (white) were activated with PHA and 
irradiated allogeneic PBMC (not shown).  To expand the viruses released from infected 
cells, CD4
+
 T lymphoblasts from healthy donors (grey) were added directly to the culture 
(standard viral outgrowth assay) or were separated from patient cells by a cell-
impermeable polyester membrane with 0.4 μm pores (transwell viral outgrowth assay). 
(C) Comparison of activation status of patient cells in standard and transwell viral 
outgrowth assay cultures, and in p24 ELISA positive and negative wells on day 21.  
HLA-A2 negative patient cells were co-cultured with HLA-A2 positive healthy donor 
CD4
+
 lymphoblasts and irradiated allogeneic PBMC.  The viable HLA-A2 negative 
population was gated as patient cells for surface activation marker analysis. 
(D) Comparison of viral outgrowth assay results by p24 ELISA of supernatants from 










Chapter 3. Characterization of non-induced proviral clones 
 
Introduction 
The non-induced proviruses had been considered to be defective through various 
mechanisms, including apolipoprotein B mRNA editing enzyme (APOBEC) mediated G-
to-A hypermutations, recombination during reverse transcription (Sanchez et al., 1997; 
Temin, 1993) and low fidelity of reverse transcriptase (3.4 x10
-5
 mutations/bp/cycle 
(Mansky and Temin, 1995)).  The incoming virus is infectious and intact upon entry, but 
becomes defective during reverse transcription.  As long as the very ends of the reverse-
transcribed proviral DNA are intact, these defective proviruses will be integrated into the 
human genome.  Based on the analysis of proviruses from acutely infected patients, at 
least one third are overtly defective (Salazar-Gonzalez et al., 2009), not including large 
internal deletions.  Cells harboring these defective proviruses, which will not produce 
viral proteins to be presented and recognized by CTLs, continue to expand through 
homeostatic proliferation.  However, these defective proviral genomes remain detectable 
by PCR-based methods, and are being used in evaluating eradication trials (Katlama et al., 
2013). Characterization of these non-induced proviruses is essential in the eradication 
effort, to avoid prolonged patient exposure to toxic latency reversing agents for 
overestimating the latent reservoir by detection of defective “graveyard” proviruses. 
The main barrier to identify full-length proviral clones is the rarity of the 
proviruses in resting CD4
+
 T cells.  Identification of full-length HIV-1 genome has been 
reported, but all from viremic patients with predominant clones in the circulation 




Gonzalez et al., 2009).  Identification of clonal non-induced proviral clones requires 
limiting dilution PCR to avoid complementing different proviral clones in one reaction, 
causing a hybrid of different proviral genomes.  Full-length proviral PCR amplification 
of single clones has been inefficient and challenging, due to the sequence variability in 
different patients and the bulk of the human genome in PCR reactions.  We here 
established a near-full-length nested PCR to identify single clones of non-induced 




Peripheral blood was obtained from healthy volunteers and HIV-1 infected donors (Table 
1) who had suppression of viremia to <50 copies HIV-1 RNA/ml for >6 months on ART 
to avoid preintegration latency(Blankson et al., 2000). This study was approved by the 
Johns Hopkins Institutional Review Board. Written informed consent was obtained from 
all participants. 
 
Characterization of full-length non-induced proviruses 
Genomic DNA was extracted from cells of p24 negative wells using Gentra Puregene 
Cell Kit (Qiagen).  Genomic DNA isolated from p24 negative wells seeded with 4 x 10
4
 




 T cells was subjected to limiting dilution prior to 
amplification with an initial near full genome length outer PCR (U5 to U5) followed 
nested amplification of a segment of the gag gene.  Aliquots were serially diluted and 




PCR reaction mixture solutions including outer PCR primers (BLOuterF and BLOuterR). 
Touchdown cycling conditions with decreasing annealing temperature were used to 
increase specificity (Table 2). Then, 2 μL aliquots from each outer PCR well were 
subjected to nested gag PCR and 1% agarose gel electrophoresis.  If <20% of the gag 
PCR wells were positive, the corresponding outer PCR wells contained one template with 
>90% of possibility, based on the Poisson distribution.  From these corresponding 
positive outer PCR wells of such plates, 2 μL aliquots were taken for each of four nested 
PCRs (A, B, C and D).  The products were directly sequenced without cloning.  
Sequences were aligned using CodonCode Sequence Assembly and Alignment Software.  
The presence of double peaks on sequencing chromatograms was taken as evidence that 
more than one template may have been present initially, and the sequence was discarded.  
Direct sequencing results were analyzed by the Los Alamos Hypermut program and 
HIVAlign program to identify hypermutation and nonsense mutations. 
 
Results 
Clonal amplification and sequencing of non-induced proviruses 
We obtained near full-length clonal sequences of non-induced proviruses from 
eight patients on suppressive ART.  Patient characteristics are in Table 1.  Non-induced 
proviruses were obtained from wells that were seeded with 4 x 10
4





 T cells and that were negative for p24 on day 21.  In clonal viral outgrowth assay 
cultures, wells with replicating virus are p24-positive by day 10 – 14 (Laird et al., 2013).  




the p24 negative wells showed exponential growth.  Thus, the non-induced proviruses 
were obtained from wells with no replicating virus despite maximal T cell activation. 
Non-induced proviruses were amplified in limiting dilution PCRs to avoid in vitro 
recombination.  A near full-length 9.1 kb outer PCR (Li et al., 2007) spanning U5 to U5 
(positions 623 – 9,686 by HXB2 coordinates) was followed by nested inner PCRs.  
Aliquots from the outer PCR were first amplified in a nested inner gag PCR (Figure 2A).  
Cell dilutions for which <20% of the inner reactions were positive were selected because 
positive wells at these dilutions have >90% probability of being clonal.  Aliquots from 
the gag-positive, clonal outer PCRs were amplified using four sets of inner PCR primers 
to obtain fragments overlapping by 150 – 3,173 bp (Figure 2A). Importantly, instead of 
cloning PCR products, we directly sequenced them.  This dramatically reduces PCR 
errors since errors occurring after the first or second cycle are present in too small a 
fraction of the final products to be observed.  Sequences with double peaks or non-
identical overlap regions were discarded.  We identified 213 non-induced proviruses from 
eight patients. 
 
Hypermutation and large internal deletions render most non-induced proviruses 
defective 
Most (88.3%) non-induced proviruses had obvious defects precluding replication 
(Figure 1C).  Direct sequencing of the nested gag PCR product revealed that ~1/3 (32.4%) 
of non-induced proviruses had APOBEC3G-mediated G→A hypermutation occurring in 
the expected sequence context (GG or GGG) (Yu et al., 2004), with the first G being 




and numerous tryptophan→stop codon mutations (Figure 3).  Although the gag gene was 
analyzed here, other regions of the genome show even greater hypermutation (Yu et al., 
2004).  Importantly, it is unlikely that hypermutated proviruses could produce functional 
viral proteins due to stop codons in most open reading frames (ORFs). 
Non-induced proviruses that were not hypermutated were further analyzed by 
nested amplification of four overlapping subgenomic fragments (Figure 2A).  Of the 144 
clonal non-induced proviruses that were not hypermutated, 97 had large internal deletions 
identified by smaller amplicon size in agarose gel electrophoresis (Figure 2B).  We 
mapped the precise deletion junctions in 58 of these clones (Figure 4A). For example, 
clone 10CB7_48H1 (Figure 2B) gave a smaller amplicon for the nested C reaction, and 
amplification of fragments A, B, and D failed due to deletion of nucleotides 4,869 – 
9,533.  All 58 mapped deletions would affect expression of the essential regulatory 
proteins Tat and Rev (Figure 4A) because the deletions encompass the tat and rev exons, 
the splice sites, and the Rev-responsive element (RRE). 
  Deletions are not unexpected.  HIV-1 is prone to recombination due to 
pseudodiploidity (two RNA copies per virion with physical proximity for recombination).  
Frequent template switching events occur during reverse transcription (Simon-Loriere 
and Holmes, 2011).  Switching between short repeats in a single genome results in 
deletion of the intervening sequence and one repeat (Temin, 1993).  Frequent large 
deletions have been observed in unfractionated PBMC from viremic patients (Sanchez et 
al., 1997).  Several lines of evidence in our analysis suggest that these deletions occur in 
vivo rather than during in vitro analysis.  First, deletions were observed following direct 




deletion junctions were observed in different nested PCRs using different primers.  Third, 
short amplicons were not seen in control experiments with plasmids carrying the 
reference proviral genomes NL4-3 and BaL.  Plasmids were mixed, diluted to eight 
copies per 100,000 human genome equivalents, and amplified under the same conditions.  
No deletion or recombination was observed.  Fourth, short sequence repeats were 
identified at some deletion junctions (Figure 2B), consistent with a single polymerase 
jump due to copy choice recombination during reverse transcription of the minus strand 
(Sanchez et al., 1997).  Taken together, these results demonstrate that a large fraction of 
non-induced proviruses are non-functional due to large internal deletions, likely 
introduced during reverse transcription. 
The precise fraction of proviruses with deletions could be underestimated by this 
analysis because deletions could affect PCR primer binding sites.  For 39 clones, the 
exact deletion junction could not be identified, probably because the deletions 
encompassed some of the binding sites for primers used in the nested PCRs.  For these 
clones, we obtained at least two sequences to ensure that the amplicons contained non-
hypermutated, patient-specific sequences.  For 12 mapped deletions, the deletion 
included the reverse gag primer binding site, but mapping was possible because other 
nested reactions were successful. 
 
Mutations in cis elements render some non-induced proviruses defective 
Proviruses with correct amplicon size were directly sequenced.  A small fraction 
(8/213) had non-sense mutations and/or frame-shifting insertions or deletions in one or 




sequences (Figure 5A). The deletions encompassed the major splice donor (MSD) site.  
Point mutations in the MSD site were found in two proviruses.  Full genome sequencing 
showed that seven of the non-induced proviruses with Ψ or MSD mutations were 
otherwise intact.  To determine whether these mutations rendered non-induced proviruses 
defective, we reconstructed three clones by genome synthesis as described below.  The 
reconstructed proviruses included two clones with short (8 bp and 16 bp) Ψ deletions in 
packaging stem loop two and one with a MSD site mutation (TG|GT→TG|GG).  
Although these clones had intact ORFs, they did not replicate in healthy donor CD4
+
 
lymphoblasts (Figure 5B) under conditions in which other reconstructed proviruses 




We show here that most non-induced proviruses were rendered defective during 
reverse transcription by APOBEC3G-induced hypermutation (Yu et al., 2004), by 
internal deletions caused by copy choice recombination during reverse transcription 
(Sanchez et al., 1997), or by frame-shift or nonsense mutations caused by the error-prone 
reverse transcriptase (Bebenek et al., 1989).  The resulting defective viral genomes can 
still integrate because only defects at the ends of the genome affect integration.  The 
defective genomes will be detected in most PCR-based assays of proviral DNA provided 
that the primer binding sites are intact.  Many of the defective proviruses have large 
internal deletions encompassing the Tat and Rev ORFs and the RRE.  Tat-mediated 




the production of virus particles requires that singly spliced and unspliced HIV-1 mRNAs 
be exported from the nucleus in a Rev-dependent fashion (Malim et al., 1989).  Thus 
these deleted proviruses may not produce viral proteins even after successful induction of 
transcription.  The same is true for hypermutated proviruses, which have stop codons in 
every ORF.  Importantly, eradication strategies depend on the production of viral proteins 
which allows recognition of the infected cells by HIV-1 specific CTL (Shan et al., 2012).  
Defective proviruses with large internal deletions and/or APOBEC3G-induced 
hypermutation may not be eliminated even by strategies that effectively eliminate cells 
carrying replication-competent virus.  These considerations highlight the difficulty of 
















Figure 2. Characterization of non-induced proviruses 
(A) Strategy and results of analysis of non-induced proviruses.  Limiting dilution viral 
outgrowth assay cultures were established from eight patients.  A total of 51 p24-negative 




 T cells were analyzed.  213 non-
induced proviruses were identified by near-full length limiting dilution PCR followed by 
a nested gag PCR.  The gag PCR products were directly sequenced, and proviruses with 
APOBEC3G-mediated G to A hypermutation were identified using the Los Alamos 
Hypermut algorithm (Rose and Korber, 2000).  Non-hypermutated proviruses were 
analyzed by nested amplification of four overlapping subgenomic fragments (labeled A–
D).  Amplicons with patient HIV-1 sequence but discernibly smaller than expected size in 
1% agarose gel electrophoresis were considered to contain large internal deletions which, 
where possible, were mapped by direct sequencing.  Other lethal defects including single 
nucleotide insertions and deletions (INDELs), packaging signal (Ψ) deletions, and major 
splice donor (MSD) site mutations were identified by direct sequencing. 
(B) Results of 1% agarose gel electrophoresis of four subgenomic amplicons (A – D) 
from representative non-induced proviruses with different defects.  Left to right: intact 
genome, 16 bp Ψ deletion, deletion with defined junction, and deletion with undefined 
junction.  Clone name is give below each gel.  Triangles, amplicons with correct size. 
Asterisks, amplicons with smaller than expected size. 










Figure 3. APOBEC3G-mediated G to A hypermutation renders some non-induced 
proviruses defective 
(A) Nucleotide sequences of the gag gene (representing nucleotides 790 – 2,292, HXB2 
coordinates) of hypermutated non-induced proviruses from a representative patient (#20). 
Sequence changes representing probable G to A hypermutation are shaded.  Sequences 
are aligned to the reference sequence HXB2 and an intact, non-induced provirus from the 
same patient. 
(B) Amino acid sequences of Gag from the hypermutated non-induced proviruses from 
(A).  Sequence changes resulting from probable G to A hypermutation are shaded.  
Sequences are aligned to the reference sequence HXB2 and an intact, non-induced 
provirus from the same patient.  Note that the methionine start codon of Gag is frequently 
mutated to isoleucine (ATG → ATA).  This is because the second amino acid of Gag is 
glycine (GGX), which results in an APOBEC3G recognition site ATGGGX, allowing 
mutation of the third position of the start codon.  Hypermutation also affects many 
tryptophan codons which contain the APOBEC3G recognition site.  Mutation of either or 
both of the G nucleotides to A generates a stop codon (TGG → TGA, TAG, or TAA, 














Figure 4. Mapping of large internal deletions in non-induced proviruses 
(A) Locations of deletions.  Dark blue horizontal bars: continuous sequencing reads 
interrupted by deletions.  White horizontal bars: deletions. Light blue vertical bars, tat 
and rev ORFs.  Gray vertical bar: RRE element. 
(B) Representative sequences at deletion junctions.  Short repeats (underlined) at the 
deletion junctions suggest a single reverse transcriptase jump due to copy choice 
recombination (Sanchez et al., 1997; Temin, 1993).  Hypermutated sequences (see Figure 









Figure 5. Deletions and mutations in cis elements 
(A) Location of cis element deletions and mutations in 14 clones from five patients.  pbs, 
tRNA primer binding site; SL, packaging stem loop; DIS, dimerization initiation site; 
MSD, major splice donor site, typically TG|GT (arrow and box).  
(B) Growth kinetics of three reconstructed clones from three patients with MSD site 
deletion or mutation but intact ORFs for all viral proteins, in comparison with the NL4-3 












Chapter 4. Intact non-induced proviruses are replication competent 
 
Introduction 
 Clonal analysis of full-length HIV-1 genomes from untreated patients has 
contributed to current understanding of HIV-1 evolution and antiviral immune responses 
(272 Li,B. 2007; 236 Salazar-Gonzalez,J.F. 2009; 274 Sahu,G.K. 2010; 297 Li,Y. 1991).  
Reconstruction of near-full-length proviruses had be reported (Gao et al., 1998)(Sahu et 
al., 2010), but existing reconstruction strategies involve combining two cloned PCR 
products, which raises the questions of combining different clones into one and 
introducing PCR errors.  Bulk PCR sequencing without cloning will only pick up the true 
sequences, as PCR induced errors will not be reported in the sequencing results.  We 
therefore choose de novo gene synthesis to these avoid cloning induced errors. 
 The replication competence of the reconstructed proviruses depends not only on 
intact open reading frames of all viral genomes, but also intact promoter (long terminal 
repeat, LTR) function and cis-acting elements, including the packaging signal (Ψ), trans-
activation response elements (TAR), ribosomal frameshift signal, polypurine tracks and 
Rev response element (RRE).  The function of these elements, with extensive secondary 
structures, may not be fully evaluated by sequence analysis alone.  Therefore, 
reconstruction of the full-length genome becomes the only way to evaluate the 
competence of non-induced proviruses, not only to understand the impact of missense 






Reconstruction of full-length non-induced proviruses 
Direct sequencing results were used for de novo genome synthesis.  The resulting 
sequences were cloned into pNL4-3 vector (GenScript Inc USA and Bio Basic Inc) by 
BssHII and NgoMIV.  To correct the 5’LTR to 100% patient derived, the plasmid 
fragments between the AatII and BssHII sites were cloned into Zero Blunt TOPO vector 
(Invitrogen) and subjected to site directed mutagenesis by QuikChange Site-Directed 
Multi Kit (Agilent Technologies, Inc).  Reconstructed plasmids were transformed into 
Stbl3 chemically competent cells (Invitrogen) and cultured at 30°C to reduce 
recombination.  The reconstructed plasmids were confirmed by restriction digestion and 
sequencing.  Induced proviruses from end-dilution viral outgrowth cultures were 
reconstructed using similar methods.  Plasmids were transfected to HEK 293T cells using 
Lipofectamine 2000 (Invitrogen).  Viruses released into the supernatants were collected 
by ultracentrifugation 48 – 72 hours after transfection.  Viruses were titered and 
normalized to 200 ng p24/mL for growth kinetics experiments.  Healthy donor CD4
+
 
lymphoblasts were infected using spinoculation (1,200 g, 25°C for two hours), and 
growth was monitored by p24 ELISA of culture supernatants.  
 
Measurement of LTR function 
Patient-derived LTR sequences were cloned into wt-LTR-Luc reporter and transfected 
into resting CD4
+
 T cells from healthy donors using nucleofection (Amaxa) (Yang et al., 
2009a).  TK-RLuc was used as internal control.  After 48 hours, basal luciferase activity 
was measured.  We also measured luciferase activity four hours after stimulation with 






Of 213 non-induced proviruses, 25 (11.7%) had intact ORFs and cis elements. 
When sequences were compared with corresponding sequences from induced proviruses 
from the same patient, no known lethal mutations were seen.  To determine whether these 
intact non-induced proviruses are replication-competent, we used the direct sequencing 
results to reconstruct full-length non-induced proviral clones by de novo genome 
synthesis (Figure 6A).  This strategy avoids PCR and cloning-induced errors.  We 
reconstructed six non-induced proviruses from four patients by inserting the synthesized 
sequence into a plasmid carrying the reference isolate NL4-3.  Not captured in our PCR 
strategy is a 108 bp segment of the provirus, representing nucleotides (nt) 565 – 672 
(HXB2 coordinates). This segment in the 5’ untranslated region includes part of U5 and 
the primer binding site (pbs) (Figure 6A).  Although U5 deletions may not affect 
replication-competence (Vicenzi et al., 1994), we took additional steps to make the 
reconstructed clones fully patient-derived, without any NL4-3 sequence.  We used 
limiting dilution PCR to amplify the LTR-gag region from cells in p24 negative wells in 
separate reactions.  Using a 424 bp segment from the 5’ U3-R-U5 region (HXB2 nt 140–
564), we constructed phylogenetic trees (Figure 7).  Then, using site-directed 
mutagenesis, we corrected the 108 bp segment from NL4-3 to the phylogenetically 
closest sequence from the same patient (Figure 6A). This process results in proviruses 
that are 100% patient-derived and 98.2 % equivalent to specific proviruses present in vivo 
with the remaining 1.8% equivalent to a very closely related provirus from the same 




estimate that the reconstructed clones could differ from the parent clones by at most 3 nt, 
or 0.03% of the genome.  For each patient, we also reconstructed an induced viral clone 
from a p24 positive well. 
Strikingly, all six reconstructed non-induced proviruses from four different 
patients showed replication fitness comparable to that of the reference isolate NL4-3 and 
reconstructed induced proviruses from the same patients (Figure 6B).  It is formally 
possible that these intact non-induced proviruses could have actually been defective, with 
an inactivating mutation in the 108 bp region that was corrected when the NL4-3 
sequence was reverted to the most closely related patient-specific sequence.  Such a 
mutation would have had to arise during reverse transcription in cell from which the 
proviral sequence was obtained. Based on measured in vivo mutation rate of 3.4x10
-5
 
mutations/bp/cycle (Mansky and Temin, 1995), the probability of a mutation arising in 
the 108 bp segment during a single cycle is only 0.0037, and only a subset of these 
mutations would be inactivating.  Importantly, all of the proviruses that we reconstructed 
were functional.  The probability that all of these actually had defects in the 108 bp 
region is (0.00324)
6
 = 1.16 x 10
-15
.  Thus we feel that it is extremely unlikely that the 
intact non-induced proviruses described here are in fact defective. This conclusion is 
further supported by experiments showing that an additional round of PHA stimulation 
causes some non-induced proviruses to produce replication-competent virus (see below).  
Taken together, these results indicate that a substantial fraction of the non-induced 
proviruses are intact and capable of generating infectious virus if induced in vivo. 
 




The ability of intact non-induced proviruses to produce infectious virus suggests 
that, at the primary sequence level, their promoters are functional.  To confirm this, we 
cloned LTRs from representative non-induced proviruses into a luciferase reporter 
construct (Yang et al., 2009a).  We measured luciferase activity in transfected resting 
CD4
+
 T cells before and four hours after stimulation with PMA and ionomycin.  We also 
analyzed LTRs from induced proviruses from the same patients and NL4-3.  In general, 
LTRs from non-induced proviruses showed basal (Figure 8A, C) and stimulated (Figure 
8B, D) activity comparable to LTRs from induced proviruses and NL4-3.  Decreased 
LTR function was only observed for hypermutated clones.  This likely reflects G→A 
hypermutation in binding sites for the transcription factors NF-κB and Sp1 (Figure 8E).  





Figure 6. Growth kinetics of reconstructed non-induced viruses 
(A) Reconstruction of full-length non-induced proviruses.  Pink, clonal patient-derived 
sequence. Blue, pNL4-3.  Purple, sequence from the most closely related patient-specific 
virus.  See text for details. 
(B) Growth kinetics of reconstructed non-induced viruses from p24 negative wells (pink 













Figure 7. Phylogenetic analysis for reconstruction of the 108 bp sequence 
(A) Use of phylogenetic analysis to reconstruct full-length patient-derived proviruses for 
six non-induced proviral clones and four induced proviral clones.  We corrected the 108 
bp segment (565 – 672, HXB2 coordinates) missing from the original PCRs (Figure 3A) 
to the most closely related sequence from the same patient. For this purpose, we used 
limiting dilution PCR to amplify the LTR-gag region from cells of p24 negative wells. 
An average of 31 clonal sequences were obtained for each patient.  Using a 424 bp 
segment from the U3-R-U5 region (HXB2 positions 140 – 564), we constructed 
phylogenetic trees and calculated the phylogenetic distance between reconstructed clones 
and each of these LTR-gag PCR sequences using a maximum likelihood estimate.  Pink 
triangles, intact non-induced proviruses to be reconstructed.  Yellow circles, induced 
proviruses from p24 positive wells from the same patient.  Open diamonds, non-induced 
proviral LTR sequences from the same patient.  Arrows, exact sequences used for 
correction, chosen based on smallest pairwise distance in a maximum likelihood 
phylogenic analysis using MEGA 5.10 software. 
(B) Nucleotide sequences of the 108 bp segment (nt 565 – 672).  Nucleotide differences 
between NL4-3 (bottom sequence) and the patient-derived sequence that was most 
closely related to the reconstructed clone (arrow) were corrected by site directed 






















Figure 8. LTR activity of non-induced proviruses 
LTR activity measured before (A, C) and four hrs after PMA/iononmycin stimulation (B, 
D). Resting CD4
+
 T cells were transfected with LTR-firefly luciferase reporter constructs 
containing LTRs from non-induced proviruses or induced proviruses from p24 positive 
wells (yellow bars).  Firefly luciferase activity was normalized to an internal control, 
Renilla luciferase driven by a constitutive thymidine kinase promoter.  The resulting 
values were then expressed relative to the NL4-3 control.  Non-induced proviruses 
included those with intact genomes (red bars), insertions or deletions (blue bars), and 
hypermutation (white bars).  Asterisks indicate different clones with the same LTR 
sequence. 
(E) Impact of G→A hypermutation on transcription factor binding sites. Hypermutated 












Chapter 5. Non-induced proviruses lack epigenetic silencing markers 
 
Introduction 
 The presence of intact genome and replication competence indicates intact non-
induced proviruses contain required viral components to become infectious once 
reactivated.  We then explored whether these non-induced proviruses are within favorable 
cellular conditions for reactivation.  First, the compact heterochromatin needs to be 
released into relaxed euchromatin for transcription factors to access binding sites 
(Tamaru, 2010).  Although several groups reported HIV-1 latency in cell-line models is 
associated with integration into heterochromatin and alphoids repeats (Blazkova et al., 
2009; Jordan et al., 2003; Verdin et al., 1993), latent clone selection process in cell line 
models may represent a biased population of integration into heterochromatin and may 
not reflect latency conditions in vivo.  Integration site analysis in patient cells suggests 
integration into active transcription units in vivo (Han et al., 2004).  Whether non-induced 
proviruses are a biased population which are integrated into heterochromatin needs to be 
investigated to understand whether they could potentially be reactivated. 
 Second, local chromatin structure is essential for transcriptionally permissive state 
(Deaton and Bird, 2011).  Unmethylated CpG at promoter region is associated with 
nucleosome displacement and constitutive RNA polymerase II binding, allowing 
transcription factors to bind (Deaton and Bird, 2011).  Methylated promoter CpG inhibits 
transcription factor binding or recruits methyl-binding domain proteins, which further 
recruit corepressor complexes and promotes histone deacetylation and therefore 




associated with heavy CpG methylation in some cell-line models (Blazkova et al., 2009; 
Kauder et al., 2009), analysis of HIV-1 promoter CpG methylation led to contradictory 
results in patient samples (Blazkova et al., 2009; Blazkova et al., 2012b).  Here we 
analyzed CpG methylation of HIV-1 promoter in non-induced proviruses to understand 
whether non-induced proviruses have favorable or unfavorable local chromatin 
environment for transcription and reactivation. 
 
Methods 
Integration site and CpG methylation 
Integration site analysis was carried out by inverse PCR as previously described 
(Han et al., 2004).  Transcription levels of the host genes containing integration sites 
were determined using a previously described serial analysis of gene expression (SAGE) 
analysis of Bcl-2-transduced primary resting and activated CD4
+ 
T cells (Shan et al., 
2011).  CpG methylation analysis was carried out at limiting dilution by bisulfite 
sequencing as described by Blazkova et al. (Blazkova et al., 2012b). 
 
Results 
Most non-induced proviruses are integrated into active transcription units 
We determined the locations of non-induced proviruses in the host genome to 
understand whether they were integrated into sites unfavorable for transcription.  
Pioneering studies by Bushman et al. showed that HIV-1 typically integrates into 
transcription units (Schroder et al., 2002).  However, in some model systems, integration 




inverse PCR at limiting dilution, we found that 92.9% of 70 non-induced proviruses 
resided in transcription units (Figure 9A), consistent with previous observations in patient 
resting CD4
+
 T cells (91%) (Han et al., 2004).  Using transcript levels measured in a 
SAGE library from a primary cell model of HIV-1 latency (Shan et al., 2011), we found 
that most non-induced proviruses were integrated into genes that were transcribed at 
moderate levels in both resting and activated CD4
+
 T cells (Figure 9B).  Non-induced 
proviruses were found in both orientations with respect to the host genes (Figure 9C).  
Overall these results indicate that non-induced proviruses are not integrated into 
chromosomal regions that are repressive for transcription, and thus other factors must 
have prevented expression of these proviruses. 
 
Lack of CpG methylation in the LTR of non-induced proviruses 
We next examined whether non-induced proviruses were epigenetically silenced.  
Unlike histone modifications, which can only be analyzed for a population, promoter 
CpG methylation status can be analyzed at the single provirus level.  CpG islands are 
present in the HIV-1 genome (Chavez et al., 2011), including one in the U3 region of the 
LTR which contains critical transcription factor binding sites (Figure 10). CpG 
methylation in the LTR could lead to recruitment of methyl-CpG binding proteins which 
mediate transcriptional silencing by recruiting nucleosome remodeling and histone 
deacetylation complexes (Kauder et al., 2009).  Therefore, DNA from freshly isolated 
resting CD4
+
 T cells and from cells in p24 negative wells was treated with bisulfite, and 
then the LTR region was amplified under limiting dilution conditions (Blazkova et al., 




3.1% of the LTR CpGs were methylated in resting CD4
+
 T cells from study patients.  
Even fewer (0.9%) of the CpGs in the LTRs of non-induced proviruses were methylated 
(Figure 10).  In contrast, we readily detected methylation at a CpG island in the env 
region (75.5%), indicating that this method did not selectively amplify non-methylated 
sites.  Although CpG methylation at the LTR clearly is well documented in some models 
of HIV-1 latency (Kauder et al., 2009), our results indicate that non-induced proviruses 
are not silenced through CpG methylation at the 5’ LTR. 
 
Discussion 
Understanding why intact non-induced proviruses did not produce infectious virus 
after maximum in vitro T cell activation is critical for determining their clinical 
significance.  Possible explanations include silencing by repressive chromatin 
modifications or transcriptional interference.  We analyzed CpG methylation of the LTRs 
of non-induced proviruses at the clonal level.  In contrast to some in vitro models of HIV-
1 latency (Kauder et al., 2009), we found that in patient CD4
+
 T cells, there was little 
CpG methylation at the LTR, consistent with another recent study (Blazkova et al., 
2012b).  We also examined whether non-induced proviruses are silenced by integration 
into heterochromatin.  We found that most of the non-induced proviruses were integrated 
into active transcription units, consistent with previous studies showing that most HIV-1 
proviruses are integrated into introns of actively transcribed genes in cell lines (Schroder 
et al., 2002) and patient resting CD4
+
 T cells (Han et al., 2004).  Another potential 
explanation for the non-induced proviruses is transcriptional interference (Han et al., 




interference due to the high affinity of NF-κB for its binding sites in the LTR (Lenasi et 






Figure 9. Integration sites of non-induced proviruses 
(A) Distribution of integration sites of non-induced proviruses.  Intron and exon 
boundaries determined as previously described (Shan et al., 2011).  Refseq, EST, Human 
mRNA and Unigene databases were used for intron and exon boundary determination.  
Other, integration sites matched with other gene or transcription databases but not Refseq. 
(B) Transcription level of host genes in which non-induced proviruses were integrated.  
Transcription levels were determined by SAGE analysis of Bcl-2 transduced activated 
and resting primary CD4
+ 
T cells as previously described (Shan et al., 2011).  Blue circles, 
transcript levels in resting and activated CD4
+
 T cells.  Red squares, transcript levels for 
the subset of genes in which integration sites of non-induced proviruses were mapped. 












Figure 10. CpG methylation of non-induced proviruses 
(A) Positions of CpGs analyzed. 
(B) CpG methylation in the 5’ LTR of proviruses in resting CD4
+
 T cells from the 
indicated patients.  Each row represents a single provirus amplified by limiting dilution 
PCR after bisulfite treatment.  Open circles, nonmethylated CpGs. Closed circles, 
methylated CpGs. Missing circles, no CpG present due to sequence polymorphism. 
(C) CpG methylation in the env gene of proviruses from resting CD4
+
 T cells. 
(D) CpG methylation in the 5’ LTR of non-induced proviruses from p24 negative wells. 















Our discovery of intact non-induced proviruses implies potential underestimation 
of the HIV-1 latent reservoir.  The viral outgrowth assay has been used as the standard 
measurement of the size of the latent reservoir, although all the latency reversing agents 
to date can only reactivate a much smaller fraction of the latent reservoir, compared with 
that of the single round of PHA activation used in viral outgrowth assay (Blazkova et al., 
2012a).  We demonstrated that intact non-induced proviruses may be an underestimated 
clinical threat in addition to the inducible reservoir by PHA activation.  Identification of 
this increased barrier challenges the shock-and-kill HIV-1 eradication strategy. 
Characterization of non-induced proviruses provides the molecular basis of HIV-1 
measurement.  Proviral DNA measurements have been used to measure the size of the 
latent reservoir.  However, we found that 88% of the proviruses are defective.  Measuring 
and monitoring defective proviruses does not reflect the true size of the clinically 
important latent reservoirs.  Rather, using PCR-based proviral DNA measurements to 
monitor the size of the latent reservoir may overestimate, leading to unnecessary and 
prolonged exposure to latency reversing agents in patients. 
Various assays had been used to measure the size of the latent reservoir with 
highly diverse results (Eriksson et al., 2013).  We demonstrated here the individual 
variability and comparison between different estimates of the most reasonable 






Quantitative DNA PCR 
Total proviral DNA in resting CD4
+
 T cells was quantified using a real-time PCR 
assay (Durand et al., 2012; Palmer et al., 2003).  Copy numbers of the human RNaseP 
gene copies were measured in separate reactions to quantify cell number (TaqMan Copy 
Number Reference Assay, RNaseP, Invitrogen) (Spivak et al., 2011). 
 
Statistical analysis 
The correlation between viral outgrowth and intact non-induced provirus 
frequency was analyzed using MedCalc software.  Bayesian inference was used to 
estimate the proportion of intact non-induced genomes in each patient.  An empirical 
Bayesian prior, among five models (Table 3), was chosen to reflect the distribution of the 





 T cells to yield an estimate of intact non-induced proviruses per million 
cells. 
 
Estimate the frequency of intact non-induced proviruses 
The number of intact proviral genomes per million cells was estimated for each 
patient by Bayesian inference, in collaboration with Sarah B. Laskey and Dr. Daniel I. S. 
Rosenbloom.  The clones examined were modeled as binomial data, with an unknown 
probability of being intact.  The probability was estimated for each patient based on five 




distribution on results.  The beta distribution is the conjugate prior for a binomial 
distribution and describes the probabilities of failure and success for a binomial 
experiment, i.e., the probability of an examined clone being intact versus defective, so all 
five priors are beta distributions with varying parameters. 
The uniform and Jeffreys prior distributions are uninformative priors, chosen to 
minimize the effect of initial assumptions (Brown et al., 2001).  The empirical Bayesian 
prior distribution was determined by calculating the sample mean and variance of the 
observed proportions of intact non-induced clones and calculating the beta distribution 
that fits those parameters.  The weighted empirical Bayesian prior has a weighted mean 
and sample variance, using the number of clones tested for each patient as the weight.  
The weighting decreases the sample variance and makes the prior stronger.  By using the 
weighting, we acknowledge the consequently strong prior and claim that if we were to 
double or triple the number of clones tested, we would probably find at least one intact 
non-induced provirus in every patient.  The three patients for whom no intact clones were 
found are also the three patients in whom the fewest clones were tested.  The iterative 
median approach started with an arbitrary prior, used the posterior median to create an 
empirical Bayes prior for the next round, and iterated until convergence.  (Using the 
empirical Bayes prior as the initial prior, 40 iterations were sufficient for convergence.) 
The empirical Bayesian priors reflect the distribution of the observed data, so 
these are not fully Bayesian analyses.  However, empirical Bayesian analysis can be 





The median and 95% credible intervals for each approach are reported in Table 3.  
To estimate the number of cells harboring intact non-induced proviruses per million 
resting CD4
+
 T cells, the median and 95% interval were multiplied by the number of cells 
carrying HIV-1 DNA per million resting CD4
+
 T cells. 
 
Results 
Although most non-induced proviruses have identifiable lethal defects, a 
substantial fraction are intact and replication-competent at the primary sequence level.  
Analysis of LTR function, integration sites, and methylation status suggests that these 
intact non-induced proviruses could be induced in vivo, thereby increasing latent 
reservoir size.  We compared the frequency of induced proviruses (defined using the viral 
outgrowth assay) and intact non-induced proviruses (quantitated as the product of total 
proviral DNA frequency and the fraction of non-induced proviruses that are intact) 
among the total pool of proviruses (measured by quantitative real-time PCR).  Bayesian 
analysis was chosen instead of maximum likelihood estimation because the former 
provides nonzero point estimates for patients from whom no clones with intact genomes 
were identified.  The positive viral outgrowth assay results in every patient and the 
successful detection of intact non-induced proviruses in patients for whom >20 clones 
were analyzed suggest that intact non-induced proviruses could be detected in every 
patient if enough clones are examined.  The fraction of intact non-induced proviruses was 
calculated as the median of an empirical Bayesian posterior, the most conservative of five 
models tested (Table 3), with a prior distribution chosen to reflect the observed data.  






 T cells varied dramatically from patient to patient (Figure 11A). 
There was no correlation between the viral outgrowth assay and the frequency of intact 
non-induced proviruses (Figure 11B).  All statistical models (Table 3) indicated that the 
median frequency of intact non-induced proviruses was at least ~60 fold higher than the 
frequency of induced proviruses detected in the viral outgrowth assay.  If the intact non-
induced proviruses described here can be induced in vivo, then the size of the latent 
reservoir is much greater than previously thought (Figure 11C). 
 
Discussion 
To prove replication-competence, we reconstructed six intact, non-induced 
proviruses from six different p24 negative wells from four patients.  Surprisingly, all 
reconstructed viruses replicated as well as the standard reference isolate and control 
viruses reconstructed from p24 positive wells.  A sterilizing cure requires elimination of 
all replication-competent HIV-1, and therefore the discovery that intact non-induced 
proviruses are replication-competent means that the number of proviruses that must be 
eliminated is much higher than previously thought.  We conservatively estimate that the 
number may be ~60 fold higher than estimates based on the viral outgrowth assay.  Some 
statistical models suggest an even higher number (medians of 97 – 273 fold).  
Importantly, there is large inter-patient variation in this and other measures of latent 
reservoir size. Overall, our results indicate that the “shock and kill” strategy (Archin et al., 
2012; Deeks, 2012) is challenged with a large but unmeasured hidden population of 
replication-competent proviruses.  Interestingly, despite the intense search for novel 




vitro HIV-1 induction achieved by PHA.  Thus the finding that the true size of the latent 
reservoir may be ~60 fold greater than that estimated using PHA activation is particularly 
disturbing.  However, it is also important to point out that the even a low level of virus 
gene expression may be sufficient to allow the elimination of infected cells by an 
appropriately primed CTL response (Shan et al., 2012), and that the critical variable may 
















































Figure 11. Quantification of intact non-induced proviruses 
(A) Comparison of the frequency of cells detected in the viral outgrowth assay, cells 
carrying intact non-induced proviruses, and cells carrying HIV-1 DNA.  The frequency of 
cells with HIV-1 DNA was measured by quantitative PCR on freshly isolated resting 
CD4
+
 T cells.  The frequency of cells with intact, non-induced proviruses was calculated 
as frequency of cells with HIV-1 DNA times the proportion of intact non-induced 
proviruses estimated for each patient using an empirical Bayesian model.  Open symbols, 
no intact proviruses detected, empirical Bayesian estimate plotted.  Bars, median value. 
(B) Correlation between the frequency of cells detected in the viral outgrowth assay and 
the frequency of cells with intact non-induced proviruses.  Open symbols, see (A). 
(C) Scale representation of the frequencies of the infected resting CD4
+
 T cell 
populations.  Volume reflects population size.  Yellow circles, minimum size of the latent 
reservoir as measured by viral outgrowth assay.  Magenta, frequency of cells with intact 
proviruses, calculated as the frequency of cells detected in the viral outgrowth assay plus 
the frequency of cells with intact non-induced proviruses.  This is the potential size of the 











Chapter 7. Stochastic activation of non-induced proviruses 
 
Introduction 
 Although non-induced proviruses were not reactivated after one round of 
maximum T cell activation in vitro, it does not mean that it will never be induced in vivo.  
Whether and why non-induced proviruses can be reactivated in vivo is the key question to 
HIV-1 eradication. 
 It has been believed that maximum T cell activation leads to maximum HIV-1 
activation.  Theoretically, our demonstration of 100% T cell activation by PHA should 
lead to 100% HIV-1 provirus reactivation, and therefore none of the non-induced 
proviruses can be reactivated.  However, HIV-1 activation may not follow T cell 
activation mechanisms.  Variable levels of Tat, which is required to form positive 
transcriptional elongation factor b (pTEFb) to released stalled RNA polymerase II from 
LTR, may lead to stochastic fluctuations and phenotypic variability(Weinberger et al., 
2005).  Viral fate determination has been proposed to be determined by transcriptional 
bursting of Tat (Singh et al., 2010; Weinberger et al., 2008).  If stochasticity is the major 
mechanism of HIV-1 reactivation, it means that every single non-induced proviruses 
might become activated due to stochasticity, and cure cannot be achieved before 
eradicating all the intact non-induced proviruses. 
 To determine whether these non-induced proviruses can be reactivated by 









 T cells from four aviremic donors were plated at 0.2 million/well 
and subjected to activation with PHA and irradiated allogeneic PBMC for one day.  
Patient cells were then cultured in a transwell viral outgrowth assay, with patient cells in 
the upper chamber along with irradiated allogeneic PBMC and donor lymphoblasts in the 
lower chamber.  On day seven, viability of cells in the upper chamber was examined by 
forward and side scattered flow cytometry.  On day seven of culture, the cells in the 
upper and lower chambers of each well were combined and then separated equally into 
duplicate culture wells.  As all patient cells had divided at least once by day seven, each 
pair of split wells should contain an approximately equal number of daughter cells 
derived from the patient cells in the original well.  One set of the split culture wells was 
subjected to an additional round of stimulation with PHA and irradiated allogeneic 
PBMC.  The other set of wells were not stimulated. Both sets of wells were cultured for 
an additional 14 days with two more additions of donor lymphoblasts.  Levels of HIV-1 
p24 antigen were measured in the supernatant on day 21. 
 
Results 
To determine whether intact non-induced proviruses are permanently silenced or 
potentially inducible under certain conditions, we tested whether repeated PHA 
stimulation can induce additional non-induced proviruses (Figure 12A).  We stimulated 
multiple replicate cultures of 2 x 10
5
 patient resting CD4
+
 T cells with PHA in viral 
outgrowth assay conditions.  We then split each culture well equally into two wells on 




contained daughter cells derived from cells activated in the original well.  One set of the 
split cultures wells were activated again with PHA while the other set was cultured 
without additional stimulation.  We then compared supernatant p24 levels after another 
14 days of culture.  Among 126 p24 negative wells from four patients, 31 (24.6%) 
became p24 positive after the additional round of PHA stimulation, while their paired 
culture well that did not receive an additional round of stimulation remained p24 negative 
(Figure 12B).  These results demonstrate that at least some intact non-induced proviruses 
can be induced under repeated stimulation. 
 
Discussion 
We propose that despite maximum T cell activation, the induction of latent 
proviruses is stochastic.  Cellular gene expression levels may follow a digital or analogue 
distribution after T cell receptor activation, as a result of stochastic and dynamic 
processes (Chakraborty and Das, 2010).  Elegant experimental and theoretical studies 
have shown that HIV-1 proviruses may show stochastic fluctuations in expression 
depending on levels of Tat (Burnett et al., 2009; Weinberger et al., 2005; Weinberger et 
al., 2005; Weinberger et al., 2008).  We propose that intact proviruses undergo stochastic 
induction even after maximum cellular activation (Figure 13).  Some will be induced by 
one round of activation, while others will remain silent but retain the potential to be 
activated subsequently.  These results indicate an increased barrier to cure, as all intact 
non-induced proviruses need to be eradicated.  Underestimation of intact proviruses by 
viral outgrowth assays could be reflected in delayed viral rebound after an apparent 




proviruses by PCR assays could result in prolonged, excessive exposure to toxic latency 
reversing agents.  Thus, the molecular analysis of non-induced proviruses contributes in 




Figure 12. Stochastic activation of non-induced proviruses 
(A) Scheme for repeated stimulation.  To understand whether non-induced proviruses 
may be induced by repeated stimuli, resting CD4
+
 T cells from four aviremic donors were 
plated at 0.2 million/well and subjected to activation with PHA and  irradiated allogeneic 
PBMC for one day.  Patients cells were then cultured in a transwell viral outgrowth assay, 
with patient cells in the upper chamber along with irradiated allogeneic PBMC and donor 
lymphoblasts in the lower chamber.  On day seven, viability of cells in the upper chamber 
was examined.  On day seven of culture, the cells in the upper and lower chambers of 
each well were combined and then separated equally into duplicate culture wells.  As all 
patient cells had divided at least once by day seven, each pair of split wells should 
contain an approximately equal number of daughter cells derived from the patient cells in 
the original well.  One set of the split culture wells was subjected to an additional round 
of stimulation with PHA and irradiated allogeneic PBMC.  The other set of wells were 
not stimulated.  Both sets of wells were cultured for an additional 14 days with two more 
additions of donor lymphoblasts.  Levels of HIV-1 p24 antigen were measured in the 
supernatant on day 21. 
(B) Comparison of p24 results for of each pair of standard and repeated stimulation 
culture wells.  Red bars: number of wells containing non-induced proviruses induced to 
produce replication competent viruses after repeated PHA stimulation.  Magenta bars: 
number of wells containing non-induced proviruses which are not induced after repeated 
PHA stimulation.  Similar results were obtained in experiments in which patient resting 
CD4
+










Figure 13. Mechanism of HIV-1 latency reactivation 
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